Latest news

• National trial to rapidly find treatments for severe flu this winter launched in UK

  Multiple treatments will be tested in the trial, including the anti-viral treatments Tamiflu (oseltamivir) and baloxavir, as well as steroids and anti-inflammatory drugs found to be effective against

• Roche’s Xofluza issued FDA approval to treat influenza in children aged five years and older

  miniSTONE-2 was a phase 3, multicentre, randomised, double-blind study that evaluated the safety, pharmacokinetics and effectiveness of a single-dose of Xofluza versus oseltamivir, in otherwise healthy children aged

• Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

  It has already been shown to be effective against a wide range of flu viruses, including those resistant to Roche’s now off-patent and former blockbuster flu treatment, Tamiflu (oseltamivir).

• Roche scores another FDA approval for Xofluza

  oseltamivr. The approval was based on results from Roche’s phase 3 CAPSTONE-2 trial of Xofluza, compared to oseltamivir or placebo, in people aged 12 or over, who met the ... However, similar efficacy results were seen between Xofluza and oseltamivir

• UK bans some drug exports to preserve NHS stocks

  It applies mainly to hormone replacement therapies but also includes all adrenaline pens, hepatitis B vaccines and the influenza drug oseltamivir, sold by Roche as Tamiflu, amongst other drugs.